Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Fails To Hit Disease-Free Survival

Executive Summary

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.

You may also be interested in...



FDA Rejects Keytruda Dosing, Fast Tracks Tecentriq Lung Cancer Review

Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first

Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits

Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.

Novartis’s Latecomer PD-1 Outshines Keytruda And Opdivo In Esophageal Cancer

Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel